Bavarian Nordic A/S announced the award of a contract valued at EUR 65 million to supply its MVA-BN smallpox vaccine to the strategic reserve within the European Union (EU) in 2025. This third, and larger order follows two previous orders, received in 2023 and delivered in 2024, for smallpox vaccines to rescEU stockpiles across Europe and will help to expand the EU?s capability to respond to future biological threats and emergencies by enabling rapid deployment of medical countermeasures to its member states.